87 related articles for article (PubMed ID: 27476488)
1. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
2. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
[TBL] [Abstract][Full Text] [Related]
3. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract][Full Text] [Related]
4. Ononin triggers ferroptosis-mediated disruption in the triple negative breast cancer both in vitro and in vivo.
Gong G; Wan Y; Liu Y; Zhang Z; Zheng Y
Int Immunopharmacol; 2024 May; 132():111959. PubMed ID: 38554442
[TBL] [Abstract][Full Text] [Related]
5. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.
Staquicini FI; Hajitou A; Driessen WH; Proneth B; Cardó-Vila M; Staquicini DI; Markosian C; Hoh M; Cortez M; Hooda-Nehra A; Jaloudi M; Silva IT; Buttura J; Nunes DN; Dias-Neto E; Eckhardt B; Ruiz-Ramírez J; Dogra P; Wang Z; Cristini V; Trepel M; Anderson R; Sidman RL; Gelovani JG; Cristofanilli M; Hortobagyi GN; Bhujwalla ZM; Burley SK; Arap W; Pasqualini R
Elife; 2021 Jun; 10():. PubMed ID: 34060472
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of LINS01 histamine H
Ospital IA; Táquez Delgado MA; Nicoud MB; Corrêa MF; Borges Fernandes GA; Andrade IW; Lauretta P; Martínez Vivot R; Comba MB; Zanardi MM; Speisky D; Uriburu JL; Fernandes JPS; Medina VA
Biomed Pharmacother; 2024 May; 174():116527. PubMed ID: 38579399
[TBL] [Abstract][Full Text] [Related]
7. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract][Full Text] [Related]
8. ROS mediated Cu[Fe(CN)
Tripathy S; Haque S; Londhe S; Das S; Norbert CC; Chandra Y; Sreedhar B; Patra CR
Biomater Adv; 2024 Jun; 160():213832. PubMed ID: 38547763
[TBL] [Abstract][Full Text] [Related]
9. Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer.
Ho AN; Kiesel VA; Gates CE; Brosnan BH; Connelly SP; Glenny EM; Cozzo AJ; Hursting SD; Coleman MF
Cells; 2024 May; 13(10):. PubMed ID: 38786030
[TBL] [Abstract][Full Text] [Related]
10. Nano-inducer of ferroptosis for targeted chemotherapy of human triple negative breast carcinoma.
Shetake NG; Das SK; Kumar A; Pandey BN
Biomater Adv; 2024 Jul; 161():213868. PubMed ID: 38677038
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic Vulnerability of Triple-negative Breast Cancer Cell-derived Tumors to Pretreatment with Vernonia amygdalina Aqueous Extracts.
Howard CB; McDowell R; Feleke K; Deer E; Stamps S; Thames E; Singh V; Pervin S
Anticancer Res; 2016 Aug; 36(8):3933-43. PubMed ID: 27466496
[TBL] [Abstract][Full Text] [Related]
12. Integrative transcriptome analysis of triple negative breast cancer profiles for identification of druggable targets.
Arumugam P; Ramesh V; Sampathkumar B; Perumalsamy H; Balusamy SR; Suganya K; Balraj S; Nachimuthu SK; Sundaravadivelu S
J Biomol Struct Dyn; 2023; 41(21):12106-12119. PubMed ID: 36617953
[TBL] [Abstract][Full Text] [Related]
13. SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration.
Xiao H; Yang X; Huang S
Cancer Chemother Pharmacol; 2023 Jan; 91(1):43-52. PubMed ID: 36436062
[TBL] [Abstract][Full Text] [Related]
14. Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation.
Tanaka N; Okada H; Yamaguchi K; Seki M; Matsubara D; Gotoh N; Suzuki Y; Furukawa Y; Yamashita T; Inoue JI; Kaneko S; Sakamoto T
Cell Death Dis; 2023 Dec; 14(12):815. PubMed ID: 38081808
[TBL] [Abstract][Full Text] [Related]
15. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
[TBL] [Abstract][Full Text] [Related]
16. Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models.
Cavanagh RJ; Monteiro PF; Moloney C; Travanut A; Mehradnia F; Taresco V; Rahman R; Martin SG; Grabowska AM; Ashford MB; Alexander C
Biomater Sci; 2024 Mar; 12(7):1822-1840. PubMed ID: 38407276
[TBL] [Abstract][Full Text] [Related]
17. Interferon-tau (IFN-τ) Has Antiproliferative Effects, Induces Apoptosis, and Inhibits Tumor Growth in a Triple-negative Breast Cancer Murine Tumor Model.
Espin-Rivera AM; Meza-Aparicio FU; Reyna-Flores F; Burguete-Garcia AI; Guzman-Olea E; Bermudez-Morales VH
In Vivo; 2023; 37(6):2517-2523. PubMed ID: 37905606
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin tartrate induces apoptosis and cytoprotective autophagy and synergizes with chemotherapy on triple negative breast cancer.
Zhang Y; Huang Q; Xu Q; Jia C; Xia Y
Biomed Pharmacother; 2023 Dec; 168():115665. PubMed ID: 37832400
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells.
Kar T; Dugam P; Shivhare S; Shetty SR; Choudhury S; Sen D; Deb B; Majumdar S; Debnath S; Das A
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2049. PubMed ID: 38522013
[TBL] [Abstract][Full Text] [Related]
20. Enhanced chemoimmunotherapy of breast cancer in mice by apolipoprotein A1-modified doxorubicin liposomes combined with interleukin-21.
An D; He P; Liu H; Wang R; Yu X; Chen N; Guo X; Li X; Feng M
J Drug Target; 2023 Dec; 31(10):1098-1110. PubMed ID: 37909691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
